AdMeTech Foundation is hosting the 7th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer. This virtual event will take place on September 21-23, 2023.
AdMeTech Foundation’s 7th Annual Global Summit Brings Together the Key International Opinion Leaders for Accelerating Advancement of Research, Clinical Care and Equity
BOSTON, MA / ACCESSWIRE / September 21, 2023 / ADMETech Foundation is hosting the 7th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer. This virtual event will take place on September 21-23, 2023.
This event has brought together the key international opinion leaders to expedite advancement of precision care for prostate cancer.
Since its establishment in 2016, AdMeTech Foundation’s Annual Global Summit has become seminal in shaping the state-of-the-art and future vision for precision care by:
1) Educating the key healthcare stakeholders;
2) Creating and supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and
3) Expediting clinical adoption of promising novel diagnostics and therapeutics.
AdMeTech Foundation’s Summit has traditionally had an extensive participation of medical professionals from North America, Europe, Australia, and Asia. For Summit 2023, AdMeTech established an International Organizing Committee, which has been instrumental in expanding global participation of physicians and scientists even further, particularly from previously under-represented regions, including the Middle East, Africa, Central and South America.
The Global Summit will review the cutting-edge advances in patient care and research, including “smart” screening, precision diagnosis and treatment. The focus of the Summit is on the integration of molecular, genetic, proteomic, imaging, and histologic diagnostics into a comprehensive diagnostic patient evaluation to ensure an individualized approach to patient care. Precision care is essential for saving lives, reducing health disparities and health care costs. To achieve this goal, the Global Summit will examine the current and future role of bioinformatics, artificial intelligence, machine and deep learning for complex clinical data analysis for selecting optimal patient management strategies.
Prostate cancer, striking one in eight men, is the most common male malignancy and the second most common cause of cancer deaths in men. Prostate cancer is a leading health disparity, causing more than two times higher mortality in Black men compared to White men.
AdMeTech Foundation organized the 7th Global Summit in cooperation with Grand Rounds in Urology, serving as the Media Partner.
This event is supported by the Commonwealth of Massachusetts and private sponsors, including Exact Imaging, Janssen Oncology (a subsidiary of Johnson and Johnson), Lantheus Imaging and Point Biopharma, Blue Earth Diagnostics, MDxHealth, Pfizer Oncology, Philips, and Siemens Healthineers, and Avenda Health.
WHAT: AdMeTech Foundation’s 7th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer
WHEN: Thursday, September 21, 8 a.m., through Saturday, September 23, 2023, 4:30 p.m.
For more information and schedule, please review here.
WHERE: Virtual Event.
WHO: Please review the scientific program here.
About AdMeTech Foundation: A 501(c)(3) nonprofit organization, based in Boston, MA. AdMeTech Foundation established the Manogram® Project, providing national and international leadership for groundbreaking programs in research, education, and awareness. These programs have been expediting advancement and clinical implementation of precision, individualized approaches to screening, diagnosis, and treatment of prostate cancer (www.admetech.org).
Contact Information
Nancy Petkunas
Vice President, Client Services, Michael P. Wasserman, Inc
npetkunas@mpwi.org
(508) 353-3357
SOURCE: AdMeTech Foundation
View source version on accesswire.com:
https://www.accesswire.com/786000/leading-experts-join-7th-annual-global-summit-on-precision-diagnosis-and-treatment-of-prostate-cancer
